Date posted: 18/02/2019 00:09:00
The European Regional Development Fund (ERDF) supports Axis with funding for Fibrosis research
A clinically relevant pulmonary fibrosis model does not currently exist; other models are on the market, but these have substantial limitations – particularly spontaneous regression of disease. Axis plans to develop a robust, clinically relevant model that will generate data that assists drug development companies in making critical go/no go decisions on their assets.......
“Generating as clinically relevant data as possible, at an early a stage in development, is a key aspect in the drug development pathway. This model will provide companies with valuable data to facilitate go/no go decisions. At present no such model for pulmonary fibrosis exists.”
Johnny McGaughey, Research Support and Operations Manager